Kristen McCarthy

Kristen McCarthy is an associate in the Business Law department and a member of its Life Science group at Goodwin. Kristen represents public and private companies in the pharmaceutical, biotechnology, and medical device industries and advises clients in a variety of corporate matters, including startup and formation matters, venture capital financings, mergers and acquisitions, initial public offerings, capital markets transactions, strategic investments, and other general corporate matters.

• Avalyn Pharma Inc. in its $345 million initial public offering
• Seaport Therapeutics, Inc. in its $255 million initial public offering
• AgomAb Therapeutics NV in its $200 million initial public offering
• The underwriters in Metsera’s $275 million initial public offering
• MBX Biosciences, Inc. in its $187 million initial public offering
• Toast, Inc. in its $1.0 billion initial public offering
• Kymera Therapeutics, Inc. in its $173.7 million initial public offering
• The underwriters in Freeline Therapeutics Holdings plc’s $158.8 million initial public offering
• Monte Rosa Therapeutics, Inc. in its $100 million and $300 million follow-on offerings
• Monte Rosa Therapeutics, Inc. in its $100 million and $100 million at-the-market offerings
• Avalyn Pharma Inc. in its $100 million Series D financing
• ARTBIO, Inc. in its $23 million Series Seed financing and $132 million Series B financing
• Mercy BioAnalytics, Inc. in its $27 million Series Seed financing, $41 million Series A financing and $59 million Series B financing
• ProMIS Neurosciences in its $122.7 million PIPE financing
• Cabaletta Bio, Inc. in its $35 million, $100 million and $150 million follow-on offerings
• Cabaletta Bio, Inc. in its $75 million, $100 million and $200 million at-the-market offerings
• scPharmaceuticals Inc. in its $50 million follow-on and $50 million at-the-market offering
• Theseus Pharmaceuticals, Inc. in its $100 million at-the-market offering
• The underwriters in Quantum Si Inc.’s $100 million at-the-market offering
• The underwriters in Evelo Biosciences Inc.’s $72.6 million follow-on offering
• The underwriters in Precigen, Inc.’s $100 million at-the-market offering
• The underwriters in Evelo Biosciences Inc.’s $75 million at-the-market offering
• The underwriters in Ambrx Biopharma Inc.’s $80 million at-the-market offering
• The underwriters in SQZ Biotechnologies Company’s $60 million at-the-market offering

While in law school, Kristen served as a law clerk in Goodwin’s REITs practice during the 2018-2019 school year and a summer associate in 2018. She was also the production editor for the Suffolk University Law Review.

Kristen was awarded the Suffolk University Law School’s Jurisprudence award for the highest grade in Criminal Law, Evidence, Contract Law, Secured Transactions and Environmental Law.

A Deferential Crisis: The Board of Immigration’s Chevron Struggle Concerning Refugee Principles, 52 Suffolk U.L. Rev. 273 (2019).